COMPARING SURVIVAL EXTRAPOLATION OUTCOMES USING DIFFERENT NETWORK META-ANALYSES (NMA) METHODS: AN APPLICATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH IMMUNOTHERAPY (IO) BASED COMBINATIONS

被引：0
|
作者：
Krol, F. [1 ]
Depalma, S. [1 ]
El Alili, H. [1 ]
Verhoek, A. [1 ]
van Beekhuizen, S. [1 ]
Heeg, B. [1 ]
机构：
[1] Cytel Inc, Rotterdam, ZH, Netherlands
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR50
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [41] Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)
    Merriman, Joseph
    Parikh, Kinjal
    Tantravahi, Srinivas Kiran
    Straubhar, Alli M.
    Agarwal, Archana M.
    Sendilnathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Grossmann, Kenneth F.
    Samlowski, Wolfram E.
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis
    Roviello, Giandomenico
    Generali, Daniele
    EUROPEAN UROLOGY, 2017, 72 (06) : 1027 - 1028
  • [43] Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors
    Graham, J.
    Wells, J. C.
    McKay, R.
    Vaishampayan, U. N.
    Hansen, A.
    Donskov, F.
    Bjarnason, G. A.
    Beuselinck, B.
    De Velasco, G.
    Duh, M. S.
    Huynh, L.
    Chang, R.
    Zanotti, G.
    Ramaswamy, K.
    Choueiri, T. K.
    Heng, D. Y. C.
    ANNALS OF ONCOLOGY, 2018, 29 : 315 - 315
  • [44] DISAGREEMENTS BETWEEN MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC) AND THE INTERNATIONAL METASTATIC RCC DATABASE CONSORTIUM (IMDC) PROGNOSTIC SCORE AND THEIR IMPACT ON SURVIVAL OUTCOMES IN CLEAR-CELL METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH TYROSINE-KINASE INHIBITORS (TKI)
    Janisch, Florian
    Marks, Phillip
    Gild, Philipp
    Meyer, Christian P.
    Fuehner, Constantin
    Dahlem, Roland
    Shariat, Shahrokh F.
    Fisch, Margit
    Rink, Michael
    JOURNAL OF UROLOGY, 2021, 206 : E257 - E258
  • [45] Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) -based regimens.
    Eid, Marc
    Labaki, Chris
    Semaan, Karl
    Saliby, Renee Maria
    Saad, Eddy
    Shah, Valisha
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma (mRCC) treated with a tyrosine kinase inhibitor (TKI) using electronic patient-reported outcomes in daily clinical practice: QUANARIE trial
    Mouillet, Guillaume
    Falcoz, Antoine
    Barthelemy, Philippe
    Geoffrois, Lionnel
    Eymard, Jean-Christophe
    Ladoire, Sylvain
    Plaza, Jerome
    Viel, Erika
    Maurina, Tristan
    Calcagno, Fabien
    Fritzsch, Joelle
    Fritzsch, Joelle
    Djoumakh, Oumelkheir
    Vernerey, Dewi
    Thiery-Vuillemin, Antoine
    Paget-Bailly, Sophie
    QUALITY OF LIFE RESEARCH, 2020, 29 (SUPPL 1) : S77 - S78
  • [47] Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs).
    Manz, Kirsi
    Fenchel, Klaus
    Eilers, Andreas
    Morgan, Jon
    Wittling, Kirsten
    Dempke, Wolfram C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial.
    Korhonen, P.
    Malangone, E.
    Sherman, S.
    Casciano, R.
    Motzer, R. J.
    Baladi, J.
    Haas, T.
    Zuber, E.
    Kay, A. C.
    Lebwohl, D. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] BAYESIAN HIERARCHICAL MODEL-BASED NETWORK META-ANALYSIS TO OVERCOME SURVIVAL EXTRAPOLATION CHALLENGES CAUSED BY IMMATURE DATA: APPLICATION IN PREVIOUSLY TREATED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PD-L1>1%
    Heeg, B.
    Verhoek, A.
    Tremblay, G.
    Chu, H.
    Roychoudhury, S.
    Cappelleri, J.
    Harari, O.
    Soltanifar, M.
    Ouwens, M.
    VALUE IN HEALTH, 2022, 25 (12) : S364 - S365
  • [50] Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018; 19:737-46 Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium
    Graham, Jeffrey
    Abdel-Rahman, Omar
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN UROLOGY, 2018, 74 (06) : E139 - E140
12345